XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development Platform
Hyderabad, India/ Shenzhen, China: January 19, 2022 – Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform.
Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR’s ADMET data will power XtalPi’s predictive models. The data helps XtalPi with high precision and predictability to confidently tackle clinical failures of new chemical entities. The well-annotated, high-quality ADMET datasets of GOSTAR are built with a proprietary QMS-ISO certified curation process powered by NLP and human intelligence.
GOSTAR provides comprehensive information encompassing over 8 million compounds, manually curated from a variety of sources including patents and journal articles. The database contains over 29 million SAR associated data points. The well-structured relational database can be utilized for diverse applications across various stages of drug discovery and development lifecycle and aids in target validation, hit identification, early lead identification, and optimization.
Min Xu, Senior Scientist, Research Manager, XtalPi Inc., said, “In XtalPi Inc., we develop advanced AI-based algorithms to tackle the challenges in the drug design process. The size and quality of datasets are always a big concern for us to build high-accuracy predictive models. That is why we consider GOSTAR as a unique and precious resource. It has millions of data points covering different compounds’ ADMET properties and is also trustful, structured, and updated. We highly recommend GOSTAR to whoever is involved in the innovation of drug design methodologies.”
Norman Azoulay, Product Leader, Excelra, said, “Artificial Intelligence and Machine Learning is bringing a paradigm shift to drug discovery and development. This partnership will help train XtalPi’s models to accurately predict efficacy and safety parameters and to ultimately increase the success rate of drug design.”
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi’s platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide. To know more, visit http://www.xtalpi.com.
About Excelra and GOSTAR
Excelra’s data and analytics solutions empower innovation in life sciences from molecule to market. The Excelra Edge comes from harmonizing heterogeneous data sets, applying innovative bioinformatics know-how and technologies to accelerate your drug discovery & development with reliable and result-oriented insights. Excelra’s GOSTAR is available as an application for users to seek, find, and discover compounds. In addition, it is offered via APIs and as a downloadable dataset to power in-house libraries and machine learning models.
For more information about GOSTAR, visit www.gostardb.com
For media inquiries, contact:
Jigesh Shah – firstname.lastname@example.org